psychoneuro 2008; 34(8): 355-360
DOI: 10.1055/s-0028-1087114
Schwerpunkt

© Georg Thieme Verlag Stuttgart · New York

Kognitive Störungen bei Multipler Sklerose – Erhebliche Auswirkungen auf Alltag und Lebensqualität

Cognitive symptoms in multiple sclerosis – Highly relevant for daily functioningChristoph Heesen1 , Jana Poettgen1 , Rüdiger Groß2
  • 1Institut für Neuroimmunologie und klinische MS–Forschung, Hamburg(Institutsdirektor: Prof. Dr. R. Martin)
  • 2Neurologisches Zentrum, Segeberger Kliniken, Bad Segeberg (Chefarzt: Prof. Dr. J. M. Valdueza)
Further Information

Publication History

Publication Date:
28 August 2008 (online)

Kognitive Störungen bei Multipler Sklerose (MS) sind lange Zeit unterschätzt worden. Mittlerweile ist eine Prävalenz von 30–70 % gesichert. Weniger klar ist der Verlauf, wobei die Datenlage bislang zeigt, dass nur bei einem Teil der Betroffenen deutlich progrediente Störungen auftreten. Hauptbetroffen sind Informationsverarbeitungsgeschwindigkeit und Aufmerksamkeit. Morphologisches Korrelat scheint weniger die Läsionslast als die degenerative Komponente der Erkrankung zu sein, die aktuell am solidesten in der Gesamthirnatrophie abgebildet ist. Die Alltagsrelevanz für Berufstätigkeit und Lebensqualität ist erheblich. Sensitive Screeninginstrumente existieren, die Korrelation zu Alltagsfunktionen ist dabei wenig untersucht. Immunmodulatoren scheinen auch die Entwicklung kognitiver Störungen abzubremsen, wobei die Datenlage hier spärlich ist. Der Nutzen von Antidementiva ist nicht gut belegt. Einige Therapiestudien deuten einen Nutzen kognitiver Rehabilitation bei MS an; die vorhandenen Studien werden in dieser Übersicht vorgestellt. Wesentliche Fragen zur Wirksamkeit der Rehabilitation wie beispielsweise der Nutzen von Kompensationstechniken vs. Trainingstechniken und die Bedeutung für den Alltag sind ungeklärt. Informationen zu kognitiven Störungen werden, wenn patientengerecht aufgearbeitet, als hilfreich empfunden und können zur Enttabuisierung des Themas beitragen.

Cognitive symptoms in multiple sclerosis have long been not recognized. The prevalence is now estimated to range between 30–70 %. Few studies exist on the long–time evolution. It seems that only a smaller subgroup of patients develops substantial progressive decline. Major domains of affection are information processing and attention. The closest association to morphological parameters on MRI is with measures of brain atrophy. The relevance of cognitive disturbances for daily living and quality of life is high. Sensitive screening instruments nowadays exist but their correlation to daily activities has not been rigorously studied. Immune modulating agents seem to slow progressive decline but again the evidence is weak. Effects of cholinergic drugs or other drugs acting on cognitive processing have not been studied in larger series. There is some evidence on the effectiveness of neuropsychological rehabilitation but as reviewed in the paper data are not conclusive on the improvement of quality of life and daily functioning. Information on cognitive disturbances is considered helpful from the patient view depending on the framing of presentation.

Literatur

  • 1 Rao SM, Leo GJ, Bernardin L, Unverzagt F.. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction.  Neurology. 1991;  41 685-691
  • 2 Amato MP, Ponziani G, Siracusa G, Sorbi S.. Cognitive dysfunction in early–onset multiple sclerosis: a reappraisal after 10 years.  Archives of neurology. 2001;  58 1602-1606
  • 3 Rao V. A. Psychiatric morbidity in the aged.  The Indian journal of medical research. 1997;  106 361-369
  • 4 Glanz BI, Holland CM, Gauthier SA. et al. . Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis.  Multiple sclerosis (Houndmills, Basingstoke, England). 2007;  13 1004-1010
  • 5 Feuillet L, Reuter F, Audoin B. et al. . Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis.  Multiple sclerosis (Houndmills, Basingstoke, England). 2007;  13 124-127
  • 6 Rao SM.. Neuropsychology of multiple sclerosis.  Current opinion in neurology. 1995;  8 216-220
  • 7 Beatty WW.. Assessment of cognitive and psychological functions in patients with multiple sclerosis: considerations for databasing.  Multiple sclerosis (Houndmills, Basingstoke, England). 1999;  5 239-243
  • 8 Amato MP, Ponziani G, Amaducci L.. Cognitive impairment in multiple sclerosis: a longitudinal study.  Electroencephalography and clinical neurophysiology. 1999;  50 465-468
  • 9 Langdon DW, Thompson AJ.. Multiple sclerosis: a preliminary study of selected variables affecting rehabilitation outcome.  Multiple sclerosis (Houndmills, Basingstoke, England). 1999;  5 94-100
  • 10 Arnett PA, Rao SM, Grafman J. et al. . Executive functions in multiple sclerosis: an analysis of temporal ordering, semantic encoding, and planning abilities.  Neuropsychology. 1997;  11 535-544
  • 11 Kujala P, Portin R, Ruutiainen J.. The progress of cognitive decline in multiple sclerosis. A controlled 3–year follow–up.  Brain. 1997;  120 289-297
  • 12 Amato MP, Ponziani G, Pracucci G. et al. . Cognitive impairment in early–onset multiple sclerosis. Pattern, predictors and impact on everyday life in a 4–year follow–up.  Arch Neurol. 1995;  52 168-172
  • 13 Achiron A, Polliack M, Rao SM. et al. . Cognitive patterns and progression in multiple sclerosis: construction and validation of percentile curves.  J Neurol Neurosurg Psychiatry. 2005;  76 744-749
  • 14 Schwid SR, Goodman AD, Weinstein A, McDermott MP, Johnson KP.. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10–year clinical trial.  J Neurol Sci. 2007;  255 57-63
  • 15 Benedict RH, Carone DA, Bakshi R.. Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis.  J Neuroimaging. 2004;  14 36-45
  • 16 Gold SM, Schulz H, Mönch A, Schulz KH, Heesen C.. Cognitive impairment in multiple sclerosis does not affect reliability and validity of self–report health measures.  Multiple sclerosis (Houndmills, Basingstoke, England). 2003;  9 404-410
  • 17 Deloire MS, Bonnet MC, Salort E. et al. . How to detect cognitive dysfunction at early stages of multiple sclerosis?.  Multiple sclerosis (Houndmills, Basingstoke, England). 2006;  12 445-452
  • 18 Sepulcre J, Vanotti S, Hernandez R. et al. . Cognitive impairment in patients with multiple sclerosis using the Brief Repeatable Battery–Neuropsychology test.  Multiple sclerosis (Houndmills, Basingstoke, England). 2006;  12 187-195
  • 19 Parmenter BA, Weinstock–Guttman B, Garg N, Munschauer F, Benedict RH.. Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test.  Multiple sclerosis (Houndmills, Basingstoke, England). 2007;  13 52-57
  • 20 Beatty WW, Goodkin DE.. Screening for cognitive impairment in multiple sclerosis. An evaluation of the Mini–Mental State Examination.  Arch Neurol. 1990;  47 297-301
  • 21 Benedict RH, Fischer JS, Archibald CJ. et al. . Minimal neuropsychological assessment of MS patients: a consensus approach.  Clinical Neuropsychology. 2002;  16 381-397
  • 22 Calabrese P, Kalbe E, Kessler J.. Das Multiple Sklerose Inventarium Cognition (MUSIC).  psychoneuro. 2004;  30 384-388
  • 23 Shawaryn MA, Schultheis MT, Garay E, Deluca J.. Assessing functional status: exploring the relationship between the multiple sclerosis functional composite and driving.  Arch Phys Med Rehabil. 2002;  83 1123-1129
  • 24 Goverover Y, Genova HM, Hillary FG, DeLuc J.. The relationship between neuropsychological measures and the Timed Instrumental Activities of Daily Living task in multiple sclerosis.  Multiple sclerosis (Houndmills, Basingstoke, England). 2007;  13 636-644
  • 25 Penner IK, Opwis K, Kappos L.. Relation between functional brain imaging, cognitive impairment and cognitive rehabilitation in patients with multiple sclerosis.  J Neurol. 2007;  254 1153-1157
  • 26 Piras MR, Magnano I, Canu ED, Paulus KS, Satta WM, Soddu A. et al. . Longitudinal study of cognitive dysfunction in multiple sclerosis: neuropsychological, neuroradiological and neurophysiological findings.  J Neurol Neurosurg Psychiatry. 2003;  74 878-885
  • 27 Benedict RH, Bruce JM, Dwyer MG. et al. . Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis.  Arch Neurol. 2006;  63 1301-1306
  • 28 Charil A, Dagher A, Lerch JP. et al. . Focal cortical atrophy in multiple sclerosis: relation to lesion load and disability.  Neuroimage. 2007;  34 509-517
  • 29 Audoin B, Au MV Duong, Malikova I. et al. . Functional magnetic resonance imaging and cognition at the very early stage of MS.  J Neurol Sci. 2006;  245 87-91
  • 30 Staffen W, Mair A, Zauner H. et al. . Cognitive function and fMRI in patients with multiple sclerosis: evidence for compensatory cortical activation during an attention task.  Brain. 2002;  125 1275-1282
  • 31 Penner IK, Rausch M, Kappos L, Opwis K, Radu EW.. Analysis of impairment related functional architecture in MS patients during performance of different attention tasks.  J Neurol. 2003;  250 461-472
  • 33 Weinstein A, Schwid SR, Schiffer RB. et al. . Neuropsychologic status in multiple sclerosis after treatment with glatiramer.  Arch Neurol. 1999;  56 319-324
  • 32 Fischer JS, Priore RL, Jacobs LD. et al. . Neuropsychological effects of interferon beta–1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group.  Ann Neurol. 2000;  48 885-892
  • 34 Greene YM, Tariot PN, Wishart H. et al. . A 12–week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments.  J Clin Psychopharmacol. 2000;  20 350-356
  • 35 Krupp LB, Christodoulou C, Melville P. et al. . Donepezil improved memory in multiple sclerosis in a randomized clinical trial.  Neurology. 2004;  63 1579-1585
  • 36 Lovera J, Bagert B, Smoot K. et al. . Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo–controlled trial.  Multiple sclerosis (Houndmills, Basingstoke, England). 2007;  13 376-385
  • 37 Heesen C, Romberg A, Gold S, Schulz KH.. Physical exercise in multiple sclerosis: supportive care or a putative disease–modifying treatment.  Expert Rev Neurother. 2006;  6 347-355
  • 38 Thomas PW, Thomas S, Hillier C, Galvin K, Baker R.. Psychological interventions for multiple sclerosis. Cochrane database of systematic reviews
  • 39 Jonsson A., Korfitzen M. E., Heltberg A., Ravnborg H. M., Byskov–Ottosen E.. Effects of neuropsychological treatment in patients with multiple sclerosis.  Acta Neurol Scand. 1993;  88 394-400
  • 40 Rodgers D, Khoo K, MacEachen M, Oven M, Beatty WW.. Cognitive therapy for multiple sclerosis: a preliminary study.  Altern Ther Health Med. 1996;  2 70-74
  • 41 Plohman AM, Kappos L, Ammann W. et al. . Computer assisted retraining of attentional impairments in patients with multiple sclerosis.  J Neurol Neurosurg Psychiatry. 1998;  64 455-462
  • 42 Mendozzi L, Pugnetti L.. Computer–assisted memory retraining of patients with multiple sclerosis.  Ital J Neurol Sci. 1998;  19 431-434
  • 43 Lincoln NB, Dent A, Harding J. et al. . Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis.  J Neurol Neurosurg Psychiatry. 2002;  72 93-98
  • 44 Lincoln B. N., Dent A., Harding J.. Treatment of cognitive problems for people with multiple sclerosis.  International Journal of Therapy and Rehabilitation. 2003;  10 412-416
  • 45 Chiaravalloti ND, Demaree H, Gaudino EA, DeLuca J.. Can the repetition effect maximize learning in multiple sclerosis?.  Clinical rehabilitation. 2003;  17 58-68
  • 46 Solari A, Motta A, Mendozzi L. et al. . Computer–aided retraining of memory and attention in people with multiple sclerosis: a randomized, double–blind controlled trial.  J Neurol Sci. 2004;  222 99-104
  • 47 Tesar N, Bandion K, Baumhackl U.. Efficacy of a neuropsychological training programme for patients with multiple sclerosis – a randomised controlled trial.  Wiener klinische Wochenschrift. 2005;  117 747-754
  • 48 Penner K. I., Kappos L., Rausch M., Opwis K., Radu W. E.. Therapy–induced plasticity of cognitive functions in MS patients: insights from fMRI.  J Physiol. 2006;  99 455-462
  • 49 Hildebrandt H, Lanz M, Hahn HK. et al. . Cognitive training in MS: effects and relation to brain atrophy.  Restor Neurol Neurosci. 2007;  25 33-43
  • 50 Heesen C, Bohm J, Reich C. et al. .Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Multiple sclerosis (Houndmills, Basingstoke, England) 2008

Korrespondenz

PD Dr. med. Christoph Heesen

Institut für Neuroimmunologie und klinische MS–Forschung

Martinstraße 52

20246 Hamburg

Email: heesen@uke.uni-hamburg.de

    >